OHSU

Stephen E.F. Spurgeon, M.D.

Head Shot of Stephen Spurgeon
Email: 
click here
Office: 
503 494-5058

Background

Dr. Spurgeon's research focuses on translating lab findings into new therapies in chronic lymphocytic leukemia and lymphoma, particularly mantle cell lymphoma.

Dr. Spurgeon has a special interest in: 1) unlocking the importance of cell signaling in lymphoid cancer pathogenesis, 2) identifying new therapeutic targets, 3) developing novel clinical trials, and 4) designing personalized treatment approaches.

CLL: Specifically, he is interested in the role of tyrosine kinases and B cell receptor (BCR) mediated signaling in leukemogenesis in chronic lymphocytic leukemia (CLL). He hopes to develop kinase directed treatment approaches for CLL. He also is interested in determining if in vitro kinase targeted drug screens can help predict in vivo response to anti-leukemic therapy. This includes collaborations with Dr. Marc Loriaux, Dr. Jeffrey Tyner and Dr. Brian Druker in the Center for Cell Signaling.

Lymphoma: In collaboration with Dr. Craig Okada at OHSU and Dr. Elliot Epner at Penn State, Dr. Spurgeon is exploring the role of epigenetic therapy in B cell malignancies especially in mantle cell lymphoma. Specifically, he is conducting an early phase clinical trial using cladribine, rituximab and vorniostat in relapsed B cell malignancies and newly diagnosed mantle cell lymphoma and CLL. This study evaluates DNA methylation patterns in patients on therapy and hopes to identify important target genes modified by this combination therapy.


Summary of Current Research

Knight Cancer Institute Clinical Research Review Committee (CRRC) Member Guest Lecturer Leukemia and Lymphoma Society

Research Interests:

Chronic lymphocytic leukemia, indolent lymphoma, intermediate and high-risk lymphoma, B-cell signaling, novel therapeutic targets, clinical trials


Selected Publications

"CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway," Leukemia (Vol: 27, Issue: 10, Page 2094-2096) - 2013

"Improved survival in hairy cell leukaemia over three decades: A SEER database analysis of prognostic factors," British Journal of Haematology (Vol: 163, Issue: 3, Page 407-409) - 2013

"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening," Cancer Research (Vol: 73, Issue: 1, Page 285-296) - 2013

"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma," New England Journal of Medicine (Vol: 369, Issue: 6, Page 507-516) - 2013

"The selective syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemias," Journal of Pharmacology and Experimental Therapeutics (Vol: 344, Issue: 2, Page 378-387) - 2013

 

Back to faculty list

OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


Contact

  Email Stephen Spurgeon

503 494-5058

Memberships & Associations

American Society of Oncology American Society of Hematology Southwest Oncology Group Alpha Omega Alpha